MediPharm Labs Announces OTC Ticker Symbol Change to “MEDIF”
09 Avril 2019 - 1:01PM
MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ)
(“MediPharm Labs” or the “Company”) a global leader in specialized,
research-driven cannabis extraction, distillation, purification and
cannabinoid isolation, today announced FINRA has approved a change
in the Company’s stock symbol trading on the OTCQB Markets.
Effective today, the Company's common shares now trade on the OTCQB
under the symbol “MEDIF”. The previous trading symbol was “MLCPF”.
There is no action required by current
shareholders in connection with this change.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the
distinction of being the first company in Canada to become a
licensed producer for cannabis oil production under the ACMPR
without first receiving a cannabis cultivation licence. This expert
focus on cannabis concentrates from our cGMP (current Good
Manufacturing Practices) and ISO standard clean rooms and critical
environments laboratory, allows MediPharm Labs to produce purified,
pharmaceutical-like cannabis oil and concentrates for advanced
derivative products. MediPharm Labs has invested in an expert,
research-driven team, state-of-the-art technology, downstream
extraction methodologies and purpose-built facilities to deliver
pure, safe and precisely-dosed cannabis products to patients and
consumers. MediPharm Labs’ private label program is a high margin
business for the Company, whereby it opportunistically procures dry
cannabis flower and trim from its numerous product supply partners,
to produce proprietary cannabis oil concentrate products for resale
globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia
Pty. Ltd., MediPharm Labs has also completed its application
process with the federal Office of Drug Control to extract and
import medical cannabis products in Australia.
For further information, please
contact: Laura Lepore, Vice President, Investor
Relations & Communications Telephone: 705-719-7425 ext
216 Email: investors@medipharmlabs.com Website:
www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning of the applicable
Canadian securities legislation. All statements, other than
statements of historical fact, are forward-looking statements and
are based on expectations, estimates and projections as at the date
of this news release. Any statement that involves discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as “expects”, or “does not expect”,
“is expected”, “anticipates” or “does not anticipate”, “plans”,
“budget”, “scheduled”, “forecasts”, “estimates”, “believes” or
“intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”,
“might” or “will” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, expected GMP certification and the
establishment of operations in Australia. Forward-looking
statements are necessarily based upon a number of estimates and
assumptions that, while considered reasonable, are subject to known
and unknown risks, uncertainties, and other factors which may cause
the actual results and future events to differ materially from
those expressed or implied by such forward-looking statements. Such
factors include, but are not limited to: general business,
economic, competitive, political and social uncertainties; the
inability of MediPharm to obtain adequate financing; and the delay
or failure to receive regulatory approvals. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, MediPharm assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change.
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024